

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**康臣葯業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1681)**

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON FRIDAY, 29 MAY 2020  
AND  
(2) CHANGE OF MEMBERS OF THE BOARD**

The Board is pleased to announce that, all the resolutions proposed were passed by the shareholders of the Company at the AGM held on Friday, 29 May 2020.

**(1) POLL RESULTS OF THE AGM**

Reference is made to the circular of Consun Pharmaceutical Group Limited (the “**Company**”) dated 29 April 2020 (the “**Circular**”) and the notice of the annual general meeting (the “**AGM**”) dated 29 April 2020. Terms used in this announcement shall have the same meaning as those defined in the Circular unless the context requires otherwise.

The board of directors of the Company (the “**Board**”) is pleased to announce that, all proposed resolutions as set out in the notice of AGM dated 29 April 2020 were passed by way of poll at the AGM held on Friday, 29 May 2020.

As at the date of the AGM, the total number of issued Shares of the Company was 844,892,980 Shares, and the total number of Shares entitling the holders to attend and vote on the resolutions at the AGM was 844,892,980 Shares. There were no Shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM. No Shareholders are required to abstain from voting at the AGM. The total number of Shares held by the Shareholders or their proxy(ies) who have attended the AGM and are entitled to vote is 469,045,478 Shares, representing approximately 55.52% of the total number of issued Shares of the Company as at the date of this announcement.

The poll results in respect of the resolutions are as follows:

Ordinary resolutions		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To receive and approve the audited consolidated financial statements together with the directors' report and the independent auditor's report of the Company for the year ended 31 December 2019.	468,771,478 (100%)	0 (0%)
2.	(a) To re-elect Mr. SU Yuanfu as an independent non-executive director of the Company.	466,268,892 (99.41%)	2,776,586 (0.59%)
	(b) To re-elect Mr. FENG Zhongshi as an independent non-executive director of the Company.	466,437,892 (99.44%)	2,607,586 (0.56%)
	(c) To authorize the board of directors of the Company to fix directors' remuneration.	469,045,478 (100%)	0 (0%)
3	To declare and pay to the shareholders of the Company a final dividend of HK\$0.1 per ordinary share of the Company for the year ended 31 December 2019.	469,045,478 (100%)	0 (0%)
4	To re-appoint KPMG as the auditors of the Company and to authorize the board of directors to fix their remuneration.	467,414,478 (99.65%)	1,631,000 (0.35%)
5.	To grant a general and unconditional mandate to the directors of the Company to allot, issue and deal with the additional ordinary shares of the Company with the total number of shares not exceeding 20% of the total number of the issued shares of the Company.	398,938,079 (85.05%)	70,107,399 (14.95%)
6.	To grant a general and unconditional mandate to the directors of the Company to repurchase shares of the Company with the total number of shares not exceeding 10% of the total number of the issued shares of the Company.	469,045,478 (100%)	0 (0%)
7.	To extend the general and unconditional mandate granted to the directors of the Company to issue, allot and deal with additional shares of the Company under resolution numbered 5 to include the number of shares of the Company repurchased pursuant to the general and unconditional mandate to repurchase shares under resolution numbered 6.	404,107,304 (86.16%)	64,938,174 (13.84%)

As more than 50% of the votes were cast in favour of each of the above resolutions, all such resolutions were duly passed by the shareholders of the Company as ordinary resolutions. The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the AGM.

## **(2) CHANGE OF MEMBERS OF THE BOARD**

### **Resignation of an executive director**

Reference is made to the announcement of the Company dated 23 March 2020. Mr. TANG Ning (“**Mr. Tang**”) has resigned from the position of an executive Director of the Company with effect upon the conclusion of the AGM held on 29 May 2020 in order to devote more time to his family. Mr. Tang has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited or the shareholders of the Company.

The Board would like to take this opportunity to express its appreciation for the valuable contributions made by Mr. Tang towards the Company during his tenure of office.

By Order of the Board  
**Consun Pharmaceutical Group Limited**  
**An Yubao**  
*Chairman*

Hong Kong, 29 May 2020

*As of the date of this announcement, the board of directors of the Company comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive directors.*